{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:40:00Z","timestamp":1791333600354,"version":"4.3.1"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["Clinician Scientist Scholar Junio 2 program"],"award-info":[{"award-number":["Clinician Scientist Scholar Junio 2 program"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012007","name":"Rockefeller University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012007","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002350","name":"St. Giles Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI088364"],"award-info":[{"award-number":["R01AI088364"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001866"],"award-info":[{"award-number":["UL1 TR001866"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Emerging Ventures","award":["Fast Grant"],"award-info":[{"award-number":["Fast Grant"]}]},{"DOI":"10.13039\/100006369","name":"George Mason University","doi-asserted-by":"publisher","award":["Mercatus Center"],"award-info":[{"award-number":["Mercatus Center"]}],"id":[{"id":"10.13039\/100006369","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yale Center for Mendelian Genomics"},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["UM1HG006504 and U24HG008956"],"award-info":[{"award-number":["UM1HG006504 and U24HG008956"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001621","name":"Fisher Center for Alzheimer's Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-IAHU-01"],"award-info":[{"award-number":["ANR-10-IAHU-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["GENCOVID"],"award-info":[{"award-number":["GENCOVID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANRS-COV05"],"award-info":[{"award-number":["ANRS-COV05"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["EQU201903007798"],"award-info":[{"award-number":["EQU201903007798"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"crossref","award":["GENCOVID"],"award-info":[{"award-number":["GENCOVID"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Square Foundation"},{"name":"Fonds de Solidarit\u00e9 pour l'enfance","award":["Grandir"],"award-info":[{"award-number":["Grandir"]}]},{"DOI":"10.13039\/100019631","name":"SCOR corporate foundation for science","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019631","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021716","name":"University of Paris","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021716","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0C8517N, G0B5120N, G0E8420N"],"award-info":[{"award-number":["G0C8517N, G0B5120N, G0E8420N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001245","name":"Jeffrey Modell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004497","name":"Onderzoeksraad, KU Leuven","doi-asserted-by":"publisher","award":["C16\/18\/007"],"award-info":[{"award-number":["C16\/18\/007"]}],"id":[{"id":"10.13039\/501100004497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007610","name":"Vlaamse Instelling voor Technologisch Onderzoek","doi-asserted-by":"publisher","award":["PID Grand Challenge"],"award-info":[{"award-number":["PID Grand Challenge"]}],"id":[{"id":"10.13039\/501100007610","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institutee Imagine MD PHD Program, FR, EU","award":["support of the Fondation Bettencourt-Schueller"],"award-info":[{"award-number":["support of the Fondation Bettencourt-Schueller"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10875-021-01068-6","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T15:03:04Z","timestamp":1623164584000},"page":"1425-1442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-\u03b2"],"prefix":"10.1007","volume":"41","author":[{"given":"Donald C.","family":"Vinh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Condino-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomeen","family":"Haerynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Pia","family":"Cicalese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Soler-Palac\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi D.","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen C.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1214-0302","authenticated-orcid":false,"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the COVID Human Genetic Effort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Arkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bolze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samya","family":"Charkravorty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Colobran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Fellay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pr Antoine","family":"Froidure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean William","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Halwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine H.","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor B.","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sediva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Tancevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Turvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"1068_CR1","unstructured":"NIH. Clinical spectrum of SARS-CoV-2 infection December 17, 2020 [Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/."},{"key":"1068_CR2","unstructured":"Johns Hopkins University & Medicine CRC. https:\/\/coronavirus.jhu.edu\/map.html 2021 ["},{"key":"1068_CR3","unstructured":"Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515)."},{"key":"1068_CR4","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515)."},{"issue":"1","key":"1068_CR5","first-page":"14","volume":"1","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang SY, Effort CHG, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med (N Y). 2020;1(1):14\u201320.","journal-title":"Med (N Y)."},{"issue":"6504","key":"1068_CR6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718\u201324.","journal-title":"Science."},{"issue":"1","key":"1068_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","volume":"146","author":"S Trouillet-Assant","year":"2020","unstructured":"Trouillet-Assant S, Viel S, Gaymard A, Pons S, Richard JC, Perret M, et al. Type I IFN immunoprofiling in COVID-19 patients. The Journal of Allergy and Clinical Immunology. 2020;146(1):206\u20138 e2.","journal-title":"The Journal of Allergy and Clinical Immunology."},{"issue":"5","key":"1068_CR8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036\u201345 e9.","journal-title":"Cell."},{"issue":"7834","key":"1068_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/d41586-020-03070-1","volume":"587","author":"E Meffre","year":"2020","unstructured":"Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. Nature. 2020;587(7834):374\u20136.","journal-title":"Nature."},{"issue":"6515","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/science.abe7591","volume":"370","author":"DB Beck","year":"2020","unstructured":"Beck DB, Aksentijevich I. Susceptibility to severe COVID-19. Science. 2020;370(6515):404\u20135.","journal-title":"Science."},{"key":"1068_CR11","doi-asserted-by":"crossref","unstructured":"Troya J, Bastard P, Planas-Serra L, Ryan P, Ruiz M, de Carranza M, et al. Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol. 2021.","DOI":"10.1007\/s10875-021-01036-0"},{"key":"1068_CR12","doi-asserted-by":"crossref","unstructured":"Koning R, Bastard P, Casanova JL, Brouwer MC, van de Beek D, with the Amsterdam UMCC-BI. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021.","DOI":"10.1007\/s00134-021-06392-4"},{"key":"1068_CR13","doi-asserted-by":"crossref","unstructured":"van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. bioRxiv. 2021.","DOI":"10.1101\/2021.03.09.434529"},{"key":"1068_CR14","doi-asserted-by":"crossref","unstructured":"Goncalves D. Antibodies against type-I Interferon: detection and association with severe clinical outcome in COVID-19 patients. medRxiv. 2021.","DOI":"10.1002\/cti2.1327"},{"key":"1068_CR15","doi-asserted-by":"publisher","unstructured":"Vazquez SE, Bastard P, Kelly K et al. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma. J Clin Immunol 2021;1\u20133. https:\/\/doi.org\/10.1007\/s10875-021-01060-0.","DOI":"10.1007\/s10875-021-01060-0"},{"issue":"6","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHOST Consortium","year":"2021","unstructured":"Consortium WHOST, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19 - interim WHO Solidarity Trial results. N Engl J Med. 2021;384(6):497\u2013511.","journal-title":"N Engl J Med."},{"key":"1068_CR17","doi-asserted-by":"publisher","first-page":"n579","DOI":"10.1136\/bmj.n579","volume":"372","author":"R Challen","year":"2021","unstructured":"Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: matched cohort study. BMJ. 2021;372:n579.","journal-title":"BMJ."},{"issue":"9","key":"1068_CR18","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.cell.2021.04.006","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2523.","journal-title":"Cell."},{"issue":"4","key":"1068_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","volume":"14","author":"A Le Bon","year":"2001","unstructured":"Le Bon A, Schiavoni G, D\u2019Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4):461\u201370.","journal-title":"Immunity."},{"issue":"16","key":"1068_CR20","first-page":"31440","volume":"S0091-6749","author":"L Moens","year":"2017","unstructured":"Moens L, Van Eyck L, Jochmans D, Mitera T, Frans G, Bossuyt X, et al. A novel kindred with inherited STAT2 deficiency and severe viral illness. The Journal of allergy and clinical immunology. 2017;S0091-6749(16):31440\u20133.","journal-title":"The Journal of allergy and clinical immunology"},{"key":"1068_CR21","doi-asserted-by":"crossref","unstructured":"Meyts I, Casanova JL. Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway. European Journal of Immunology. 2021.","DOI":"10.1002\/eji.202048793"},{"key":"1068_CR22","unstructured":"Bastard P. Anti-IFN autoantibodies and YFV disease. The Journal of Experimental Medicine. 2021."},{"issue":"6","key":"1068_CR23","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI138745","volume":"130","author":"EM Bloch","year":"2020","unstructured":"Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757\u201365.","journal-title":"J Clin Invest."},{"issue":"9","key":"1068_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695\u2013703.","journal-title":"Nat Rev Microbiol."},{"issue":"Suppl 1","key":"1068_CR25","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","volume":"52","author":"S Pandey","year":"2012","unstructured":"Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52(Suppl 1):65S\u201379S.","journal-title":"Transfusion."},{"issue":"7821","key":"1068_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","volume":"584","author":"AM Arvin","year":"2020","unstructured":"Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584(7821):353\u201363.","journal-title":"Nature."},{"key":"1068_CR27","volume":"10","author":"KL Chai","year":"2020","unstructured":"Chai KL, Valk SJ, Piechotta V, Kimber C, Monsef I, Doree C, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;10:CD013600.","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"1068_CR28","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cmi.2020.08.005","volume":"26","author":"DJ Wooding","year":"2020","unstructured":"Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436\u201346.","journal-title":"Clin Microbiol Infect."},{"key":"1068_CR29","doi-asserted-by":"crossref","unstructured":"Vegivinti CTR, Pederson JM, Saravu K, Gupta N, Evanson KW, Kamrowski S, et al. Efficacy of convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Clin Apheresis. 2021.","DOI":"10.1002\/jca.21881"},{"issue":"7","key":"1068_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vazquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619\u201329.","journal-title":"N Engl J Med."},{"issue":"7","key":"1068_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa2033700","volume":"384","author":"R Libster","year":"2021","unstructured":"Libster R, Perez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610\u20138.","journal-title":"N Engl J Med."},{"issue":"6","key":"1068_CR32","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/trf.15843","volume":"60","author":"P Barone","year":"2020","unstructured":"Barone P, DeSimone RA. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion. 2020;60(6):1123\u20137.","journal-title":"Transfusion."},{"issue":"10","key":"1068_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/eji.202048723","volume":"50","author":"K Subbarao","year":"2020","unstructured":"Subbarao K, Mordant F, Rudraraju R. Convalescent plasma treatment for COVID-19: tempering expectations with the influenza experience. Eur J Immunol. 2020;50(10):1447\u201353.","journal-title":"Eur J Immunol."},{"issue":"3","key":"1068_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. The New England journal of medicine. 2021;384(3):229\u201337.","journal-title":"The New England journal of medicine."},{"issue":"3","key":"1068_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. The New England Journal of Medicine. 2021;384(3):238\u201351.","journal-title":"The New England Journal of Medicine."},{"issue":"7","key":"1068_CR36","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.2021.0202","volume":"325","author":"RL Gottlieb","year":"2021","unstructured":"Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. Jama. 2021;325(7):632\u201344.","journal-title":"Jama."},{"issue":"6531","key":"1068_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.abf9302","volume":"371","author":"TN Starr","year":"2021","unstructured":"Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850\u20134.","journal-title":"Science."},{"issue":"21","key":"1068_CR38","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMra1009433","volume":"367","author":"EW Gelfand","year":"2012","unstructured":"Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367(21):2015\u201325.","journal-title":"N Engl J Med."},{"issue":"3","key":"1068_CR39","doi-asserted-by":"publisher","first-page":"ofaa102","DOI":"10.1093\/ofid\/ofaa102","volume":"7","author":"W Cao","year":"2020","unstructured":"Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infectious Diseases. 2020;7(3):ofaa102.","journal-title":"Open Forum Infectious Diseases"},{"issue":"1","key":"1068_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","volume":"9","author":"L Lin","year":"2020","unstructured":"Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections. 2020;9(1):727\u201332.","journal-title":"Emerging Microbes & Infections."},{"key":"1068_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.05.006","volume":"548","author":"N Mohtadi","year":"2020","unstructured":"Mohtadi N, Ghaysouri A, Shirazi S, Sara A, Shafiee E, Bastani E, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology. 2020;548:1\u20135.","journal-title":"Virology."},{"issue":"10","key":"1068_CR42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.21037\/atm-20-3305","volume":"8","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yang Y, Yang N, Ma Y, Zhou Q, Li W, et al. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review. Annals of Translational Medicine. 2020;8(10):625.","journal-title":"Annals of Translational Medicine."},{"key":"1068_CR43","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3389\/fimmu.2020.01660","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu X, Cao W, Li T. High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Frontiers in Immunology. 2020;11:1660.","journal-title":"Frontiers in Immunology."},{"issue":"40","key":"1068_CR44","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.15585\/mmwr.mm6940e1","volume":"69","author":"SB Morris","year":"2020","unstructured":"Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection - United Kingdom and United States, March-August 2020. MMWR Morbidity and Mortality Weekly Report. 2020;69(40):1450\u20136.","journal-title":"MMWR Morbidity and Mortality Weekly Report."},{"key":"1068_CR45","doi-asserted-by":"crossref","unstructured":"Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. Jama. 2021.","DOI":"10.1001\/jama.2021.0694"},{"issue":"10","key":"1068_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1192","volume":"9","author":"Z Shao","year":"2020","unstructured":"Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clinical & Translational Immunology. 2020;9(10):e1192.","journal-title":"Clinical & Translational Immunology."},{"key":"1068_CR47","doi-asserted-by":"publisher","first-page":"107205","DOI":"10.1016\/j.intimp.2020.107205","volume":"90","author":"P Tabarsi","year":"2021","unstructured":"Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A, et al. Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial. Int Immunopharmacol. 2021;90:107205.","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"1068_CR48","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","volume":"20","author":"N Gharebaghi","year":"2020","unstructured":"Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20(1):786.","journal-title":"BMC Infect Dis."},{"issue":"3","key":"1068_CR49","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"HH Peter","year":"2020","unstructured":"Peter HH, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. The Journal of Allergy and Clinical Immunology. 2020;146(3):479\u201391.e5.","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"10","key":"1068_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/00043426-200310000-00011","volume":"25","author":"M Benesch","year":"2003","unstructured":"Benesch M, Kerbl R, Lackner H, Berghold A, Schwinger W, Triebl-Roth K, et al. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. Journal of Pediatric Hematology\/Oncology. 2003;25(10):797\u2013800.","journal-title":"Journal of Pediatric Hematology\/Oncology."},{"issue":"10","key":"1068_CR51","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA van Doorn","year":"2008","unstructured":"van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome. The Lancet Neurology. 2008;7(10):939\u201350.","journal-title":"The Lancet Neurology."},{"issue":"8","key":"1068_CR52","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med."},{"issue":"13","key":"1068_CR53","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"JAC Sterne","year":"2020","unstructured":"Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama. 2020;324(13):1330\u201341.","journal-title":"Jama."},{"issue":"24","key":"1068_CR54","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333\u201344.","journal-title":"N Engl J Med."},{"issue":"1","key":"1068_CR55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","volume":"181","author":"O Hermine","year":"2021","unstructured":"Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32\u201340.","journal-title":"JAMA Intern Med."},{"issue":"1","key":"1068_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","volume":"181","author":"C Salvarani","year":"2021","unstructured":"Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24\u201331.","journal-title":"JAMA Intern Med."},{"key":"1068_CR57","doi-asserted-by":"crossref","unstructured":"Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021.","DOI":"10.1056\/NEJMoa2028700"},{"issue":"5","key":"1068_CR58","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.medmal.2020.05.001","volume":"50","author":"T Klopfenstein","year":"2020","unstructured":"Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and\/or mortality in COVID-19 patients. Med Mal Infect. 2020;50(5):397\u2013400.","journal-title":"Med Mal Infect."},{"issue":"1","key":"1068_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20\u201330.","journal-title":"N Engl J Med."},{"key":"1068_CR60","doi-asserted-by":"publisher","first-page":"n84","DOI":"10.1136\/bmj.n84","volume":"372","author":"VC Veiga","year":"2021","unstructured":"Veiga VC, Prats J, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84.","journal-title":"BMJ."},{"key":"1068_CR61","unstructured":"Investigators R-C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021."},{"key":"1068_CR62","doi-asserted-by":"crossref","unstructured":"Rubin EJ, Longo DL, Baden LR. Interleukin-6 receptor inhibition in Covid-19 - cooling the inflammatory soup. N Engl J Med. 2021.","DOI":"10.1056\/NEJMe2103108"},{"issue":"8","key":"1068_CR63","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","volume":"204","author":"M Gadina","year":"2020","unstructured":"Gadina M, Chisolm DA, Philips RL, McInness IB, Changelian PS, O\u2019Shea JJ. Translating JAKs to Jakinibs. J Immunol. 2020;204(8):2011\u201320.","journal-title":"J Immunol."},{"issue":"2","key":"1068_CR64","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/art.37785","volume":"65","author":"BR Lauwerys","year":"2013","unstructured":"Lauwerys BR, Hachulla E, Spertini F, Lazaro E, Jorgensen C, Mariette X, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013;65(2):447\u201356.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"1068_CR65","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","volume":"147","author":"I Meyts","year":"2020","unstructured":"Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. The Journal of Allergy and Clinical Immunology. 2020;147(2):520\u201331.","journal-title":"The Journal of Allergy and Clinical Immunology."},{"key":"1068_CR66","unstructured":"Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. The New England Journal of Medicine. 2020."},{"issue":"19","key":"1068_CR67","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813\u201326.","journal-title":"N Engl J Med."},{"issue":"1","key":"1068_CR68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","volume":"146","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. The Journal of Allergy and Clinical Immunology. 2020;146(1):137\u201346 e3.","journal-title":"The Journal of Allergy and Clinical Immunology."},{"issue":"17","key":"1068_CR69","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2011-12-395707","volume":"119","author":"SK Browne","year":"2012","unstructured":"Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, et al. Anti-CD20 (rituximab) therapy for anti-IFN-\u03b3 autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012;119(17):3933\u20139.","journal-title":"Blood."},{"issue":"6","key":"1068_CR70","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/cid\/cit809","volume":"58","author":"CA Czaja","year":"2014","unstructured":"Czaja CA, Merkel PA, Chan ED, Lenz LL, Wolf ML, Alam R, et al. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-\u03b3 autoantibody. Clinical Infectious Diseases. 2014;58(6):e115\u20138.","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"1068_CR71","doi-asserted-by":"publisher","first-page":"ofz131","DOI":"10.1093\/ofid\/ofz131","volume":"6","author":"A Yerramilli","year":"2019","unstructured":"Yerramilli A, Huang GKL, Griffin DWJ, Kong KL, Muhi S, Muttucumaru RS, et al. Disseminated nontuberculous mycobacterial infection associated with acquired immunodeficiency due to anti-interferon \u03b3 autoantibodies. Open Forum Infectious Diseases. 2019;6(4):ofz131.","journal-title":"Open Forum Infectious Diseases"},{"issue":"5","key":"1068_CR72","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.anai.2016.02.003","volume":"116","author":"R Naik","year":"2016","unstructured":"Naik R, Cortes JA. Persistent Mycobacterium abscessus infection secondary to interferon-\u03b3 autoantibodies. Annals of Allergy, Asthma & Immunology. 2016;116(5):461\u20132.","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2","key":"1068_CR73","doi-asserted-by":"publisher","first-page":"ofw093","DOI":"10.1093\/ofid\/ofw093","volume":"3","author":"N Pruetpongpun","year":"2016","unstructured":"Pruetpongpun N, Khawcharoenporn T, Damronglerd P, Suthiwartnarueput W, Apisarnthanarak A, Rujanavej S, et al. Disseminated Talaromyces marneffei and Mycobacterium abscessus in a patient with anti-interferon-\u03b3 autoantibodies. Open Forum Infectious Diseases. 2016;3(2):ofw093.","journal-title":"Open Forum Infectious Diseases"},{"key":"1068_CR74","first-page":"m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ (Clinical research ed). 2020;370:m3176.","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"1068_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28010","volume":"67","author":"E Even-Or","year":"2020","unstructured":"Even-Or E, Naser Eddin A, Shadur B, Dinur Schejter Y, Najajreh M, Zelig O, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatric Blood & Cancer. 2020;67(1):e28010.","journal-title":"Pediatric Blood & Cancer."},{"key":"1068_CR76","doi-asserted-by":"publisher","first-page":"602102","DOI":"10.3389\/fneur.2020.602102","volume":"11","author":"D Ratuszny","year":"2020","unstructured":"Ratuszny D, Skripuletz T, Wegner F, Gro\u00df M, Falk C, Jacobs R, et al. Case report: daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis. Frontiers in Neurology. 2020;11:602102.","journal-title":"Frontiers in Neurology."},{"key":"1068_CR77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S252592","volume":"17","author":"A Bag-Ozbek","year":"2021","unstructured":"Bag-Ozbek A, Hui-Yuen JS. Emerging B-cell therapies in systemic lupus erythematosus. Therapeutics and Clinical Risk Management. 2021;17:39\u201354.","journal-title":"Therapeutics and Clinical Risk Management."},{"key":"1068_CR78","doi-asserted-by":"crossref","unstructured":"Ochoa S, Ding L, Kreuzburg S, Treat J, Holland SM, Zerbe CS. Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-IFN-\u03b3 autoantibodies. Clin Infect Dis 2020.","DOI":"10.1093\/cid\/ciaa1086"},{"issue":"9","key":"1068_CR79","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/art.41380","volume":"72","author":"B Fallet","year":"2020","unstructured":"Fallet B, Kyburz D, Walker UA. Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment. Arthritis & Rheumatology (Hoboken, NJ). 2020;72(9):1581\u20132.","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"issue":"1","key":"1068_CR80","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1136\/annrheumdis-2020-217555","volume":"80","author":"S Monti","year":"2021","unstructured":"Monti S, Montecucco C. Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al. Annals of the Rheumatic Diseases. 2021;80(1):e11.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"1068_CR81","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2020-217948","volume":"79","author":"C Sanchez-Piedra","year":"2020","unstructured":"Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, R\u00faa-Figueroa \u00cd, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the Rheumatic Diseases. 2020;79(7):988\u201390.","journal-title":"Annals of the Rheumatic Diseases."},{"issue":"12","key":"1068_CR82","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","volume":"40","author":"J Loarce-Martos","year":"2020","unstructured":"Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F, Garcia-Garcia V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015\u201321.","journal-title":"Rheumatol Int."},{"issue":"12","key":"1068_CR83","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00296-020-04715-0","volume":"40","author":"CS Kow","year":"2020","unstructured":"Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40(12):2117\u20138.","journal-title":"Rheumatol Int."},{"issue":"5","key":"1068_CR84","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/pai.13263","volume":"31","author":"A Soresina","year":"2020","unstructured":"Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Foc\u00e0 E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatric Allergy and Immunology. 2020;31(5):565\u20139.","journal-title":"Pediatric Allergy and Immunology"},{"issue":"1","key":"1068_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","volume":"146","author":"I Quinti","year":"2020","unstructured":"Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. The Journal of allergy and clinical immunology. 2020;146(1):211\u20133.e4.","journal-title":"The Journal of allergy and clinical immunology"},{"issue":"1","key":"1068_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1203475418811335","volume":"23","author":"KA Papp","year":"2019","unstructured":"Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. Journal of Cutaneous Medicine and Surgery. 2019;23(1):50\u201374.","journal-title":"Journal of Cutaneous Medicine and Surgery."},{"issue":"2","key":"1068_CR87","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/bjh.16863","volume":"190","author":"S Thibaud","year":"2020","unstructured":"Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. British Journal of Haematology. 2020;190(2):e73\u2013e6.","journal-title":"British Journal of Haematology."},{"key":"1068_CR88","doi-asserted-by":"crossref","unstructured":"Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48).","DOI":"10.1126\/sciimmunol.abd0110"},{"key":"1068_CR89","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3389\/fonc.2020.01578","volume":"10","author":"I Kos","year":"2020","unstructured":"Kos I, Balensiefer B, Roth S, Ahlgrimm M, Sester M, Schmidt T, et al. Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Frontiers in Oncology. 2020;10:1578.","journal-title":"Frontiers in Oncology."},{"issue":"11","key":"1068_CR90","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.clml.2020.08.017","volume":"20","author":"H Yasuda","year":"2020","unstructured":"Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 2020;20(11):774\u20136.","journal-title":"Clinical Lymphoma, Myeloma & Leukemia."},{"issue":"5","key":"1068_CR91","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.semarthrit.2020.06.013","volume":"50","author":"J Leipe","year":"2020","unstructured":"Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W. Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Seminars in Arthritis and Rheumatism. 2020;50(5):1087\u20138.","journal-title":"Seminars in Arthritis and Rheumatism."},{"key":"1068_CR92","doi-asserted-by":"crossref","unstructured":"Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A. Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2\/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al. Annals of the rheumatic diseases. 2020.","DOI":"10.1136\/annrheumdis-2020-218686"},{"issue":"3","key":"1068_CR93","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of Clinical Apheresis. 2019;34(3):171\u2013354.","journal-title":"Journal of Clinical Apheresis."},{"issue":"5","key":"1068_CR94","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3892\/etm.2015.2340","volume":"9","author":"T Ishikawa","year":"2015","unstructured":"Ishikawa T, Abe S, Kojima Y, Sano T, Iwanaga A, Seki KI, et al. Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-beta\/ribavirin. Exp Ther Med. 2015;9(5):1646\u201350.","journal-title":"Exp Ther Med."},{"issue":"5","key":"1068_CR95","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4103\/ijn.IJN_64_17","volume":"27","author":"K Jagdish","year":"2017","unstructured":"Jagdish K, Jacob S, Varughese S, David VG, Mohapatra A, Valson A, et al. Effect of double filtration plasmapheresis on various plasma components and patient safety: a prospective observational cohort study. Indian J Nephrol. 2017;27(5):377\u201383.","journal-title":"Indian J Nephrol."},{"issue":"2","key":"1068_CR96","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/1744-9987.12240","volume":"19","author":"X Liu","year":"2015","unstructured":"Liu X, Zhang Y, Xu X, Du W, Su K, Zhu C, et al. Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9): a cohort study. Ther Apher Dial. 2015;19(2):178\u201384.","journal-title":"Ther Apher Dial."},{"issue":"2","key":"1068_CR97","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PCC.0b013e3181e2a569","volume":"12","author":"P Patel","year":"2011","unstructured":"Patel P, Nandwani V, Vanchiere J, Conrad SA, Scott LK. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A--an associated respiratory failure and hemodynamic shock. Pediatr Crit Care Med. 2011;12(2):e87\u20139.","journal-title":"Pediatr Crit Care Med."},{"issue":"5","key":"1068_CR98","first-page":"455","volume":"130","author":"SH Adeli","year":"2020","unstructured":"Adeli SH, Asghari A, Tabarraii R, Shajari R, Afshari S, Kalhor N, et al. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series. Pol Arch Intern Med. 2020;130(5):455\u20138.","journal-title":"Pol Arch Intern Med."},{"issue":"1","key":"1068_CR99","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s13054-020-03171-3","volume":"24","author":"C Morath","year":"2020","unstructured":"Morath C, Weigand MA, Zeier M, Speer C, Tiwari-Heckler S, Merle U. Plasma exchange in critically ill COVID-19 patients. Crit Care. 2020;24(1):481.","journal-title":"Crit Care."},{"issue":"9","key":"1068_CR100","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/0885066620940259","volume":"35","author":"S Tabibi","year":"2020","unstructured":"Tabibi S, Tabibi T, Conic RRZ, Banisaeed N, Streiff MB. Therapeutic plasma exchange: a potential management strategy for critically ill COVID-19 patients. J Intensive Care Med. 2020;35(9):827\u201335.","journal-title":"J Intensive Care Med."},{"issue":"23","key":"1068_CR101","doi-asserted-by":"publisher","first-page":"12526","DOI":"10.1073\/pnas.2006691117","volume":"117","author":"S Kesici","year":"2020","unstructured":"Kesici S, Yavuz S, Bayrakci B. Get rid of the bad first: therapeutic plasma exchange with convalescent plasma for severe COVID-19. Proceedings of the National Academy of Sciences of the United States of America. 2020;117(23):12526\u20137.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America."},{"issue":"6","key":"1068_CR102","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jfma.2020.04.023","volume":"119","author":"JH Lin","year":"2020","unstructured":"Lin JH, Chen YC, Lu CL, Hsu YN, Wang WJ. Application of plasma exchange in association with higher dose CVVH in cytokine storm complicating COVID-19. J Formos Med Assoc. 2020;119(6):1116\u20138.","journal-title":"J Formos Med Assoc."},{"key":"1068_CR103","doi-asserted-by":"publisher","first-page":"108408","DOI":"10.1016\/j.clim.2020.108408","volume":"214","author":"J Ma","year":"2020","unstructured":"Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clinical Immunology (Orlando, Fla). 2020;214:108408.","journal-title":"Clinical Immunology (Orlando, Fla)"},{"issue":"2","key":"1068_CR104","doi-asserted-by":"publisher","first-page":"105974","DOI":"10.1016\/j.ijantimicag.2020.105974","volume":"56","author":"H Shi","year":"2020","unstructured":"Shi H, Zhou C, He P, Huang S, Duan Y, Wang X, et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. Int J Antimicrob Agents. 2020;56(2):105974.","journal-title":"Int J Antimicrob Agents."},{"issue":"1","key":"1068_CR105","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13256-020-02577-5","volume":"15","author":"S Aminimoghaddam","year":"2021","unstructured":"Aminimoghaddam S, Afrooz N, Nasiri S, Motaghi Nejad O, Mahmoudzadeh F. A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report. J Med Case Rep. 2021;15(1):104.","journal-title":"J Med Case Rep."},{"key":"1068_CR106","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bbi.2020.05.022","volume":"87","author":"L Dogan","year":"2020","unstructured":"Dogan L, Kaya D, Sarikaya T, Zengin R, Dincer A, Akinci IO, et al. Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain, Behavior, and Immunity. 2020;87:155\u20138.","journal-title":"Brain, Behavior, and Immunity."},{"issue":"1","key":"1068_CR107","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s13054-020-03215-8","volume":"24","author":"B Gucyetmez","year":"2020","unstructured":"Gucyetmez B, Atalan HK, Sertdemir I, Cakir U, Telci L. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. Critical care (London, England). 2020;24(1):492.","journal-title":"Critical care (London, England)"},{"issue":"1","key":"1068_CR108","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13054-020-02943-1","volume":"24","author":"PM Honore","year":"2020","unstructured":"Honore PM, Mugisha A, Kugener L, Redant S, Attou R, Gallerani A, et al. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure. Crit Care. 2020;24(1):226.","journal-title":"Crit Care."},{"issue":"1","key":"1068_CR109","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s13054-020-03070-7","volume":"24","author":"K Stahl","year":"2020","unstructured":"Stahl K, Bode C, David S. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Crit Care. 2020;24(1):363.","journal-title":"Crit Care."},{"issue":"1","key":"1068_CR110","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13054-020-2836-4","volume":"24","author":"P Keith","year":"2020","unstructured":"Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128.","journal-title":"Crit Care."},{"issue":"1","key":"1068_CR111","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s13063-020-04454-4","volume":"21","author":"F Faqihi","year":"2020","unstructured":"Faqihi F, Alharthy A, Alodat M, Asad D, Aletreby W, Kutsogiannis DJ, et al. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): a structured summary of a randomized controlled trial study protocol. Trials. 2020;21(1):506.","journal-title":"Trials."},{"key":"1068_CR112","doi-asserted-by":"publisher","first-page":"100327","DOI":"10.1016\/j.ensci.2021.100327","volume":"22","author":"C Ranganathan","year":"2021","unstructured":"Ranganathan C, Fusinski SD, Obeid IM, Ismail KM, Ferguson DT, Raminick MF, et al. Therapeutic plasma exchange for persistent encephalopathy associated with Covid-19. eNeurologicalSci. 2021;22:100327.","journal-title":"eNeurologicalSci."},{"issue":"7803","key":"1068_CR113","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(73)90714-9","volume":"1","author":"TC Merigan","year":"1973","unstructured":"Merigan TC, Reed SE, Hall TS, Tyrrell DA. Inhibition of respiratory virus infection by locally applied interferon. Lancet (London, England). 1973;1(7803):563\u20137.","journal-title":"Lancet (London, England)"},{"issue":"25","key":"1068_CR114","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. The New England journal of medicine. 1986;315(25):1575\u20138.","journal-title":"The New England journal of medicine."},{"issue":"9","key":"1068_CR115","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrgastro.2010.101","volume":"7","author":"A Aghemo","year":"2010","unstructured":"Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nature Reviews Gastroenterology & Hepatology. 2010;7(9):485\u201394.","journal-title":"Nature Reviews Gastroenterology & Hepatology."},{"issue":"4","key":"1068_CR116","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","volume":"25","author":"FC Lin","year":"2014","unstructured":"Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine & Growth Factor Reviews. 2014;25(4):369\u201376.","journal-title":"Cytokine & Growth Factor Reviews."},{"key":"1068_CR117","doi-asserted-by":"crossref","unstructured":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet (London, England). 1998;352(9139):1498-504.","DOI":"10.1016\/S0140-6736(98)03334-0"},{"issue":"7","key":"1068_CR118","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/0883073813488828","volume":"28","author":"SN Tenembaum","year":"2013","unstructured":"Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. Journal of Child Neurology. 2013;28(7):849\u201356.","journal-title":"Journal of Child Neurology."},{"issue":"5","key":"1068_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063480","volume":"8","author":"T Kalincik","year":"2013","unstructured":"Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PloS one. 2013;8(5):e63480.","journal-title":"PloS one."},{"issue":"4","key":"1068_CR120","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","volume":"8","author":"MS Sulkowski","year":"2011","unstructured":"Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature Reviews Gastroenterology & Hepatology. 2011;8(4):212\u201323.","journal-title":"Nature Reviews Gastroenterology & Hepatology."},{"issue":"3","key":"1068_CR121","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","volume":"25","author":"T Okanoue","year":"1996","unstructured":"Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. Journal of Hepatology. 1996;25(3):283\u201391.","journal-title":"Journal of Hepatology."},{"issue":"2","key":"1068_CR122","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","volume":"19","author":"CL Raison","year":"2005","unstructured":"Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105\u201323.","journal-title":"CNS Drugs."},{"issue":"5797","key":"1068_CR123","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/289496a0","volume":"289","author":"A Vallbracht","year":"1981","unstructured":"Vallbracht A, Treuner J, Flehmig B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature. 1981;289(5797):496\u20137.","journal-title":"Nature."},{"key":"1068_CR124","doi-asserted-by":"publisher","first-page":"583560","DOI":"10.3389\/fimmu.2020.583560","volume":"11","author":"N Dunn","year":"2020","unstructured":"Dunn N, Fogdell-Hahn A, Hillert J, Spelman T. Long-term consequences of high titer neutralizing antibodies to interferon-\u03b2 in multiple sclerosis. Frontiers in immunology. 2020;11:583560.","journal-title":"Frontiers in immunology."},{"key":"1068_CR125","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.12659\/MSM.907876","volume":"24","author":"LL Aruna","year":"2018","unstructured":"Aruna LL. Anti-interferon alpha antibodies in patients with high-risk BCR\/ABL-negative myeloproliferative neoplasms treated with recombinant human interferon-\u03b1. Medical Science Monitor. 2018;24:2302\u20139.","journal-title":"Medical Science Monitor"},{"issue":"22","key":"1068_CR126","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJM198806023182201","volume":"318","author":"RG Steis","year":"1988","unstructured":"Steis RG, Smith JW 2nd, Urba WJ, Clark JW, Itri LM, Evans LM, et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. The New England Journal of Medicine. 1988;318(22):1409\u201313.","journal-title":"The New England Journal of Medicine."},{"issue":"1","key":"1068_CR127","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12916-020-01769-6","volume":"18","author":"TFM Andlauer","year":"2020","unstructured":"Andlauer TFM, Link J, Martin D, Ryner M, Hermanrud C, Grummel V, et al. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. BMC Medicine. 2020;18(1):298.","journal-title":"BMC Medicine."},{"issue":"8","key":"1068_CR128","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/jir.2020.0130","volume":"40","author":"S Pellegrini","year":"2020","unstructured":"Pellegrini S, Uze G. An old cytokine against a new virus? J Interferon Cytokine Res. 2020;40(8):425\u20138.","journal-title":"J Interferon Cytokine Res."},{"issue":"3","key":"1068_CR129","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","volume":"28","author":"N Wang","year":"2020","unstructured":"Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020;28(3):455\u201364 e2.","journal-title":"Cell Host Microbe."},{"key":"1068_CR130","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","volume":"11","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-alpha2b treatment for COVID-19. Front Immunol. 2020;11:1061.","journal-title":"Front Immunol."},{"issue":"2","key":"1068_CR131","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","volume":"9","author":"PD Monk","year":"2021","unstructured":"Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196\u2013206.","journal-title":"Lancet Respir Med."},{"issue":"10238","key":"1068_CR132","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IF Hung","year":"2020","unstructured":"Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695\u2013704.","journal-title":"Lancet."},{"key":"1068_CR133","doi-asserted-by":"crossref","unstructured":"Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9).","DOI":"10.1128\/AAC.01061-20"},{"key":"1068_CR134","doi-asserted-by":"publisher","first-page":"106903","DOI":"10.1016\/j.intimp.2020.106903","volume":"88","author":"H Rahmani","year":"2020","unstructured":"Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon beta-1b in treatment of severe COVID-19: a randomized clinical trial. Int Immunopharmacol. 2020;88:106903.","journal-title":"Int Immunopharmacol."},{"key":"1068_CR135","doi-asserted-by":"publisher","first-page":"106688","DOI":"10.1016\/j.intimp.2020.106688","volume":"85","author":"F Dastan","year":"2020","unstructured":"Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, et al. Subcutaneous administration of interferon beta-1a for COVID-19: a non-controlled prospective trial. Int Immunopharmacol. 2020;85:106688.","journal-title":"Int Immunopharmacol."},{"key":"1068_CR136","doi-asserted-by":"publisher","first-page":"592543","DOI":"10.3389\/fphar.2020.592543","volume":"11","author":"A Mary","year":"2020","unstructured":"Mary A, Henaut L, Macq PY, Badoux L, Cappe A, Poree T, et al. Rationale for COVID-19 treatment by nebulized interferon-beta-1b-literature review and personal preliminary experience. Front Pharmacol. 2020;11:592543.","journal-title":"Front Pharmacol."},{"issue":"2","key":"1068_CR137","doi-asserted-by":"publisher","first-page":"106052","DOI":"10.1016\/j.ijantimicag.2020.106052","volume":"56","author":"SI Hong","year":"2020","unstructured":"Hong SI, Ryu BH, Chong YP, Lee S, Kim S, Kim HC, et al. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir\/ritonavir, hydroxychloroquine, and interferon beta-1b. Int J Antimicrob Agents. 2020;56(2):106052.","journal-title":"Int J Antimicrob Agents."},{"issue":"13","key":"1068_CR138","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. Jama. 2020;324(13):1317\u201329.","journal-title":"Jama."},{"issue":"1","key":"1068_CR139","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s13063-020-04864-4","volume":"21","author":"E Bosi","year":"2020","unstructured":"Bosi E, Bosi C, Rovere Querini P, Mancini N, Calori G, Ruggeri A, et al. Interferon beta-1a (IFNbeta-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. Trials. 2020;21(1):939.","journal-title":"Trials."},{"issue":"1","key":"1068_CR140","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/s13063-020-04812-2","volume":"21","author":"I Alavi Darazam","year":"2020","unstructured":"Alavi Darazam I, Hatami F, Rabiei MM, Pourhoseingholi MA, Moradi O, Shokouhi S, et al. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. Trials. 2020;21(1):880.","journal-title":"Trials."},{"issue":"Pt 3","key":"1068_CR141","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1099\/vir.0.061911-0","volume":"95","author":"BJ Hart","year":"2014","unstructured":"Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. The Journal of General Virology. 2014;95(Pt 3):571\u20137.","journal-title":"The Journal of General Virology."},{"issue":"9380","key":"1068_CR142","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","volume":"362","author":"J Cinatl","year":"2003","unstructured":"Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet. 2003;362(9380):293\u20134.","journal-title":"Lancet."},{"key":"1068_CR143","doi-asserted-by":"publisher","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","volume":"179","author":"E Mantlo","year":"2020","unstructured":"Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179:104811.","journal-title":"Antiviral Res."},{"issue":"17","key":"1068_CR144","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa2015294","volume":"383","author":"YM Arabi","year":"2020","unstructured":"Arabi YM, Asiri AY, Assiri AM, Balkhy HH, Al Bshabshe A, Al Jeraisy M, et al. Interferon beta-1b and lopinavir-ritonavir for Middle East respiratory syndrome. N Engl J Med. 2020;383(17):1645\u201356.","journal-title":"N Engl J Med."},{"key":"1068_CR145","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ijid.2020.11.008","volume":"102","author":"F Khamis","year":"2021","unstructured":"Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;102:538\u201343.","journal-title":"Int J Infect Dis."},{"issue":"5","key":"1068_CR146","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","volume":"20","author":"OT Tsang","year":"2020","unstructured":"To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565\u201374.","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"1068_CR147","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/icb.2011.109","volume":"90","author":"P Hillyer","year":"2012","unstructured":"Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunology and Cell Biology. 2012;90(8):774\u201383.","journal-title":"Immunology and Cell Biology."},{"issue":"11","key":"1068_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003773","volume":"9","author":"S Crotta","year":"2013","unstructured":"Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathogens. 2013;9(11):e1003773.","journal-title":"PLoS Pathogens."},{"key":"1068_CR149","doi-asserted-by":"crossref","unstructured":"Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S, et al. Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. Journal of Virology. 2020;94(19).","DOI":"10.1128\/JVI.00985-20"},{"issue":"7830","key":"1068_CR150","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon 3rd","year":"2020","unstructured":"Dinnon KH 3rd, Leist SR, Sch\u00e4fer A, Edwards CE, Martinez DR, Montgomery SA, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560\u20136.","journal-title":"Nature."},{"key":"1068_CR151","unstructured":"Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respiratory Med."},{"issue":"1","key":"1068_CR152","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s41467-021-22177-1","volume":"12","author":"P Jagannathan","year":"2021","unstructured":"Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, et al. Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021;12(1):1967.","journal-title":"Nat Commun."},{"issue":"6504","key":"1068_CR153","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.abc2061","volume":"369","author":"J Major","year":"2020","unstructured":"Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science. 2020;369(6504):712\u20137.","journal-title":"Science."},{"issue":"6504","key":"1068_CR154","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1126\/science.abc3545","volume":"369","author":"A Broggi","year":"2020","unstructured":"Broggi A, Ghosh S, Sposito B, Spreafico R, Balzarini F, Lo Cascio A, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369(6504):706\u201312.","journal-title":"Science."}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01068-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-021-01068-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-021-01068-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T18:19:38Z","timestamp":1675448378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-021-01068-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":154,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1007\/s10875-021-01068-6","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"26 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval required. Consent to publish not applicable. Consent to publish not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement; Consent to Participate; Consent to Publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}